Vyriad, Inc. Press Releases

• Published on May 17, 2022 - 11:00 GMT

  

  Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

  ROCHESTER, MINNESOTA, UNITED STATES, May 17, 2022 /⁨EINPresswire.com⁩/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry …

  Distribution channels: Agriculture, Farming & Forestry Industry, Business & Economy ...
• Published on April 5, 2022 - 19:17 GMT

  

  Oral Vaccine Boosts COVID Immunity

  ROCHESTER, MINNESOTA, US, April 5, 2022 /⁨EINPresswire.com⁩/ -- Oral Vaccine Boosts COVID Immunity Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on August 24, 2021 - 00:00 GMT

  

  Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors

  Harry is a highly regarded Life Sciences Investor, previously served as CIO and Treasurer to Mayo Clinic ROCHESTER, MINNESOTA, USA, August 23, 2021 /⁨EINPresswire.com⁩/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...